Aytu BioPharma Inc(AYTU) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -4.58 | Insider Own | 8.36% | Shs Outstand | 10.7M | Perf Week | -10.09% |
| Market Cap | 0.02B | Forward P/E | - | EPS next Y | 92.45% | Insider Trans | - | Shs Float | 9.8M | Perf Month | -14.6% |
| Enterprise Value | 0.02B | PEG | - | EPS next Q | -0.29 | Inst Own | 35.93% | Short Float | 3.27% | Perf Quarter | -8.48% |
| Income | -0.03B | P/S | 0.39 | EPS this Y | 53.1% | Inst Trans | -4.42% | Short Ratio | 12.66 | Perf Half Y | -21.15% |
| Sales | 0.06B | P/B | 0.63 | EPS next 5Y | - | ROA | -28.93% | Short Interest | 0.32M | Perf YTD | -21.15% |
| Book/sh | 3.27 | P/C | 0.82 | EPS past 3/5Y | 88.66% 48.61% | ROE | -97.42% | 52W High | -33.12% ($3.07) | Perf Year | -10.09% |
| Cash/sh | 2.49 | P/FCF | 13.41 | Sales past 3/5Y | -11.78% 19.16% | ROIC | -74.66% | 52W Low | 24.23% ($1.65) | Perf 3Y | 24.24% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -2264.65% | Gross Margin | 60.09% | Volatility(W/M) | 4.03% 3.41% | Perf 5Y | -96.88% |
| Dividend TTM | - | EV/Sales | 0.32 | Sales Y/Y TTM | -18.24% | Oper. Margin | -12.19% | ATR (14) | 0.09 | Perf 10Y | -100% |
| Dividend Ex-Date | - | Quick Ratio | 1 | EPS Q/Q | -353.08% | Profit Margin | -60.17% | RSI (14) | 33.03 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.12 | Sales Q/Q | -32.74% | SMA20 | -9.96% ($2.28) | Beta | 0.18 | Target Price | $9.5 |
| Payout | - | Debt/Eq | 0.65 | Earnings | 2026/5/13 | SMA50 | -8.4% ($2.24) | Rel Volume | 1.13 | Prev Close | $2.12 |
| Employees | 83 | LT Debt/Eq | 0.3 | EPS/Sales Surpr. | -19.56% 2.97% | SMA200 | -14.05% ($2.39) | Avg Volume(3M) | 0.03M | Price | $2.05 |
| IPO | 2008/9/24 | Option/Short | No/Yes | Trades | 158 | Volume | 28,780 | Change | -3.3% |
Company
AYTU is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
A U.S. commercial-stage specialty pharmaceutical company that sells ADHD treatments Adzenys and Cotempla, pediatric prescription medications Karbinal and Poly-Vi-Flor, and is advancing the commercialization of EXXUA, a treatment for major depressive disorder (MDD).
Over the past 1 year, roughly in the middle
33% below its 1-year high.
AYTU has weak earning power
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +53.1% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 2 quarters.
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by +24.2% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 35.9%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
DCOR 0.00%
DFAC 0.00%
DFAS 0.00%
DFSU 0.00%
VTI 0.00%It ranks #4 in the industry
Based on market cap of $22M.
AYTU $22M PER -
TAK $58B PER -
TEVA $42B PER 61.1
HLN $41B PER 19.0
FAQ
What kind of company is AYTU?
AYTU belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of AYTU?
The market cap of AYTU is approximately $22M, ranking 5,247 within its sector.
What is the 52-week high and low for AYTU?
AYTU has recorded a 52-week high of $3.07 and a low of $1.65.
